American Thyroid Association guidelines for the management of medullary thyroid carcinoma

[1]  H. Naganuma,et al.  Carcinoma , 2020, Definitions.

[2]  P. Trimboli,et al.  Detection rate of FNA cytology in medullary thyroid carcinoma: a meta‐analysis , 2015, Clinical endocrinology.

[3]  E. Papini,et al.  Medullary thyroid cancer diagnosis: An appraisal , 2014, Head & neck.

[4]  J. Varhaug,et al.  Surgical Curability of Medullary Thyroid Cancer in Multiple Endocrine Neoplasia 2B: A Changing Perspective , 2014, Annals of surgery.

[5]  M. Pelizzo,et al.  Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. , 2014, The Journal of clinical endocrinology and metabolism.

[6]  Á. Pinto.  Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma , 2014, Cancer Chemotherapy and Pharmacology.

[7]  P. Trimboli,et al.  Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study , 2014, Clinical endocrinology.

[8]  M. Castro,et al.  Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred. , 2013, Thyroid : official journal of the American Thyroid Association.

[9]  C. Sekulla,et al.  Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury , 2013, Head & neck.

[10]  G. Cote,et al.  The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. , 2013, The Journal of clinical endocrinology and metabolism.

[11]  Kathryn J. Rowland,et al.  Pheochromocytoma in an 8‐year‐old patient with multiple endocrine neoplasia type 2A: Implications for screening , 2013, Journal of surgical oncology.

[12]  L. Groussin,et al.  Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. , 2013, The New England journal of medicine.

[13]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[14]  S. Steinberg,et al.  Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma , 2013, Clinical Cancer Research.

[15]  J. Cerutti,et al.  Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: An appraisal of p.Y791 F and p.C634Y RET mutations in five unrelated Brazilian families , 2013, Journal of Endocrinological Investigation.

[16]  M. Schlumberger,et al.  Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. , 2013 .

[17]  E. Fliers,et al.  Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. , 2013, European journal of endocrinology.

[18]  T. Imai,et al.  High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. , 2013, European journal of endocrinology.

[19]  A. García-Martín,et al.  Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment , 2013, Therapeutic advances in endocrinology and metabolism.

[20]  H. Dralle,et al.  Benefit-Risk Balance of Reoperation for Persistent Medullary Thyroid Cancer , 2013, Annals of surgery.

[21]  S. Asa,et al.  Precursor lesions of endocrine system neoplasms , 2013, Pathology.

[22]  C. Simón,et al.  The impact of next-generation sequencing technology on preimplantation genetic diagnosis and screening. , 2013, Fertility and sterility.

[23]  M. Kreissl,et al.  Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. , 2013, Thyroid : official journal of the American Thyroid Association.

[24]  H. Holzhausen,et al.  Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin , 2013, Langenbeck's Archives of Surgery.

[25]  L. Wood,et al.  Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. , 2013, The Journal of clinical endocrinology and metabolism.

[26]  H. Dralle,et al.  Prognostic Impact of N Staging in 715 Medullary Thyroid Cancer Patients: Proposal for a Revised Staging System , 2013, Annals of surgery.

[27]  K. Lorenz,et al.  Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. , 2013, The Journal of clinical endocrinology and metabolism.

[28]  E. Navarro,et al.  Non-Invasive Prenatal Diagnosis of Multiple Endocrine Neoplasia Type 2A Using COLD-PCR Combined with HRM Genotyping Analysis from Maternal Serum , 2012, PloS one.

[29]  V. Colantuoni,et al.  Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 mutation of the RET proto‐oncogene , 2012, Clinical endocrinology.

[30]  M. Borrello,et al.  Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. , 2012, Thyroid : official journal of the American Thyroid Association.

[31]  A. Lenzi,et al.  Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics , 2012, Journal of oncology.

[32]  S. Broutin,et al.  Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. , 2012, The Journal of clinical endocrinology and metabolism.

[33]  A. Pinchera,et al.  Advances in the follow-up of differentiated or medullary thyroid cancer , 2012, Nature Reviews Endocrinology.

[34]  H. C. Fan,et al.  Noninvasive Prenatal Measurement of the Fetal Genome , 2012, Nature.

[35]  A. Pinchera,et al.  Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[36]  C. Deswarte,et al.  RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation , 2012, Leukemia.

[37]  E. Baudin,et al.  Role of prophylactic thyroidectomy in RET 790 familial medullary thyroid carcinoma , 2012, Head & neck.

[38]  H. Dralle,et al.  Biological relevance of medullary thyroid microcarcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[39]  M. Pelizzo,et al.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[40]  Hang-Seok Chang,et al.  Skip Lateral Neck Node Metastases in Papillary Thyroid Carcinoma , 2012, World Journal of Surgery.

[41]  Yong-xue Zhu,et al.  Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. , 2012, The Journal of clinical endocrinology and metabolism.

[42]  F. Bonichon,et al.  Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma. , 2012, Thyroid : official journal of the American Thyroid Association.

[43]  A. Pinchera,et al.  The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. , 2012, The Journal of clinical endocrinology and metabolism.

[44]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Castaldi,et al.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  G. Valk,et al.  Unilateral Subtotal Adrenalectomy for Pheochromocytoma in Multiple Endocrine Neoplasia Type 2 Patients: A Feasible Surgical Strategy , 2011, Annals of surgery.

[47]  H. Minn,et al.  Complementary Roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in Medullary Thyroid Cancer , 2011, The Journal of Nuclear Medicine.

[48]  G. Daniels.  Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. , 2011, Thyroid : official journal of the American Thyroid Association.

[49]  M. Miccoli,et al.  No Outcome Differences between a Laparoscopic and Retroperitoneoscopic Approach in Synchronous Bilateral Adrenal Surgery , 2011, World Journal of Surgery.

[50]  J. Cerutti,et al.  The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. , 2011, Thyroid : official journal of the American Thyroid Association.

[51]  G. Cote,et al.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood , 2011, Nature Reviews Endocrinology.

[52]  J. Wexler.  Approach to the thyroid cancer patient with bone metastases. , 2011, The Journal of clinical endocrinology and metabolism.

[53]  E. Levy-Lahad,et al.  Preimplantation genetic diagnosis (PGD) – prevention of the birth of children affected with endocrine diseases , 2011, Journal of pediatric endocrinology & metabolism : JPEM.

[54]  S. Lietman.  Preimplantation genetic diagnosis for hereditary endocrine disease. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[55]  P. Chanson,et al.  Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. , 2011, The Journal of clinical endocrinology and metabolism.

[56]  A. Tabarin,et al.  Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. , 2011, The Journal of clinical endocrinology and metabolism.

[57]  V. Leite,et al.  High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. , 2011, The Journal of clinical endocrinology and metabolism.

[58]  M. Rosenthal,et al.  Pediatric Ethics Guidelines for Hereditary Medullary Thyroid Cancer , 2011, International journal of pediatric endocrinology.

[59]  T. Kiehl,et al.  Brain metastasis from medullary thyroid carcinoma , 2010, BMJ Case Reports.

[60]  C. Sekulla,et al.  Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. , 2010, Surgery.

[61]  S. Wajner,et al.  Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. , 2010, Thyroid : official journal of the American Thyroid Association.

[62]  Herb Chen,et al.  The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer , 2010, Pancreas.

[63]  J. Romijn,et al.  Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. , 2010, The Journal of clinical endocrinology and metabolism.

[64]  P. Schneider,et al.  Adjuvant external beam radiation for medullary thyroid carcinoma , 2010, Journal of surgical oncology.

[65]  C. Sekulla,et al.  Management of lymph fistulas in thyroid surgery , 2010, Langenbeck's Archives of Surgery.

[66]  H. Dralle,et al.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[67]  L. Paz-Ares,et al.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[68]  M. Knopp,et al.  Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. Waguespack,et al.  Multiple endocrine neoplasia [corrected] syndrome type 2B in early childhood: long-term benefit of prophylactic thyroidectomy. , 2010, Cancer.

[70]  N. Lee,et al.  The role of radiation therapy in the treatment of medullary thyroid cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[71]  S. Mukhopadhyay,et al.  Synchronous Metastatic Medullary and Papillary Thyroid Carcinomas in a Patient with Germline RET Mutation: Case Report, Molecular Analysis, and Implications for Pathogenesis , 2010, Endocrine pathology.

[72]  M. Walz,et al.  Single-Access Retroperitoneoscopic Adrenalectomy (SARA) Versus Conventional Retroperitoneoscopic Adrenalectomy (CORA): A Case–Control Study , 2010, World Journal of Surgery.

[73]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.

[74]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Tae Yong Kim,et al.  Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental , 2010, Clinical endocrinology.

[76]  J. McGrath,et al.  New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis , 2009, The British journal of dermatology.

[77]  M. Walter,et al.  Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer , 2009, Cancer.

[78]  P. Tam,et al.  Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing. , 2009, Hong Kong medical journal = Xianggang yi xue za zhi.

[79]  W. Burke,et al.  Duty to warn at-risk family members of genetic disease. , 2009, The virtual mentor : VM.

[80]  S. Toledo,et al.  Hypercalcitoninemia is not Pathognomonic of Medullary Thyroid Carcinoma , 2009, Clinics.

[81]  S. Gruber,et al.  Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. , 2009, Thyroid : official journal of the American Thyroid Association.

[82]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[83]  P. Bernante,et al.  Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation , 2009, Familial Cancer.

[84]  R. Weigel,et al.  When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation? , 2009, Annals of Surgical Oncology.

[85]  J. Hugot,et al.  Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. , 2009, European journal of endocrinology.

[86]  Rong Mao,et al.  Multiple endocrine neoplasia type 2 RET protooncogene database: Repository of MEN2‐associated RET sequence variation and reference for genotype/phenotype correlations , 2009, Human mutation.

[87]  A. Algeciras-Schimnich,et al.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[88]  H. Dralle,et al.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT , 2009, European Radiology.

[89]  D. Kondziolka,et al.  Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer , 2009, Journal of Neuro-Oncology.

[90]  S. Hess,et al.  Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis. , 2008, Surgery.

[91]  S. Roman,et al.  Pediatric endocrine surgery: who is operating on our children? , 2008, Surgery.

[92]  T. Economopoulos,et al.  Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. , 2008, European journal of endocrinology.

[93]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  T. Links,et al.  Radiofrequency ablation of hepatic metastases from thyroid carcinoma. , 2008, Thyroid : official journal of the American Thyroid Association.

[95]  C. Pirich,et al.  Long‐term prognosis of medullary thyroid carcinoma , 2008, Clinical endocrinology.

[96]  J. Vieira,et al.  Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. , 2008, Thyroid : official journal of the American Thyroid Association.

[97]  S. Rivkees,et al.  Clinical and economic outcomes of thyroid and parathyroid surgery in children. , 2008, The Journal of clinical endocrinology and metabolism.

[98]  L. Santarpia,et al.  Four patients with cutaneous metastases from medullary thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[99]  P. Schneider,et al.  Prognostic Value of Lymph Node Yield and Metastatic Lymph Node Ratio in Medullary Thyroid Carcinoma , 2008, Annals of Surgical Oncology.

[100]  J. Usuda,et al.  Airway stenting for the treatment of laryngotracheal stenosis secondary to thyroid cancer , 2008, Respirology.

[101]  S. Roman,et al.  Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. , 2008, The Journal of clinical endocrinology and metabolism.

[102]  R. Tsang,et al.  External beam radiation therapy for thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.

[103]  S. Hauptmann,et al.  Prediction of lateral lymph node metastases in medullary thyroid cancer , 2008, The British journal of surgery.

[104]  E. D. de Vries,et al.  18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation , 2008, Journal of Nuclear Medicine.

[105]  E. Baudin,et al.  Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. , 2008, European journal of endocrinology.

[106]  J. Roh,et al.  Prospective Identification of Chyle Leakage in Patients Undergoing Lateral Neck Dissection for Metastatic Thyroid Cancer , 2008, Annals of Surgical Oncology.

[107]  R. Spielmann,et al.  Limitations of Intraoperative Adrenal Remnant Volume Measurement in Patients Undergoing Subtotal Adrenalectomy , 2008, World Journal of Surgery.

[108]  J. Moley,et al.  Long-term Outcome of Reoperations for Medullary Thyroid Carcinoma , 2008, World Journal of Surgery.

[109]  J. Moley,et al.  Pheochromocytoma penetrance varies by RET mutation in MEN 2A. , 2007, Surgery.

[110]  P. Caron,et al.  Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. , 2007, European journal of endocrinology.

[111]  C. Rochlitz,et al.  Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial , 2007, Clinical Cancer Research.

[112]  E. Baudin,et al.  Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. , 2007, The Journal of clinical endocrinology and metabolism.

[113]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[114]  E. Voest,et al.  A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[115]  A. Miyauchi,et al.  Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. , 2007, Thyroid : official journal of the American Thyroid Association.

[116]  S. Delorme,et al.  Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. , 2007, European journal of endocrinology.

[117]  S. Hauptmann,et al.  Increased Risk of Lymph Node Metastasis in Multifocal Hereditary and Sporadic Medullary Thyroid Cancer , 2007, World Journal of Surgery.

[118]  Thomas J Lynch,et al.  A phase II study of gefitinib in patients with advanced thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[119]  M. Piga,et al.  Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[120]  A. Toniato,et al.  Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[121]  H. Dralle,et al.  Genotype-Phenotype Based Surgical Concept of Hereditary Medullary Thyroid Carcinoma , 2007, World Journal of Surgery.

[122]  S. Larson,et al.  Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels , 2007, Journal of Nuclear Medicine.

[123]  D. Yannoukakos,et al.  A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. , 2007, Hormones.

[124]  S. Hauptmann,et al.  Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. , 2007, Archives of surgery.

[125]  M. Maranghi,et al.  Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. , 2007, The Journal of clinical endocrinology and metabolism.

[126]  K. Offit,et al.  Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. , 2006, JAMA.

[127]  K. Kaczirek,et al.  Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. , 2006, Archives of surgery.

[128]  B. Wolffenbuttel,et al.  Determinants of life expectancy in medullary thyroid cancer: age does not matter , 2006, Clinical endocrinology.

[129]  M. Santoro,et al.  RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. , 2006, European journal of endocrinology.

[130]  G. Karanikas,et al.  T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. , 2006, Anticancer research.

[131]  K. Offit,et al.  Cancer genetic testing and assisted reproduction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  R. Ravazzolo,et al.  The immediate upstream sequence of the mouse Ret gene controls tissue-specific expression in transgenic mice. , 2006, International journal of molecular medicine.

[133]  H. Buhr,et al.  Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. , 2006, European journal of endocrinology.

[134]  T. de Baère,et al.  Chemoembolization for liver metastases from medullary thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[135]  D. Yannoukakos,et al.  A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening , 2006, Clinical endocrinology.

[136]  J. Dušková,et al.  Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds. , 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[137]  Y. Murakumo,et al.  RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease , 2006, Pathology international.

[138]  M. Langlois,et al.  "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. , 2006, The Journal of clinical endocrinology and metabolism.

[139]  M. Oberholzer,et al.  Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[140]  Jacques Barbet,et al.  Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[141]  Shan Wang,et al.  Mixed medullary-follicular thyroid carcinoma: Report of a case and review of the literature , 2005 .

[142]  M. Barbagallo,et al.  Dissimilar PTH, Gastrin, and Calcitonin Responses to Oral Calcium and Peptones in Hypocalciuric Hypercalcemia, Primary Hyperparathyroidism, and Normal Subjects: A Useful Tool for Differential Diagnosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[143]  A. Richardson,et al.  Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations , 2005, Clinical endocrinology.

[144]  C. Sekulla,et al.  Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. , 2005, Surgery.

[145]  F. Kraeber-Bodéré,et al.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[146]  K. Owzar,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. , 2005, The New England journal of medicine.

[147]  L. Nieman,et al.  Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. , 2005, The Journal of clinical endocrinology and metabolism.

[148]  J. Moley,et al.  Medullary thyroid carcinoma: Management of lymph node metastases , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[149]  H. Lehnert,et al.  Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. , 2005, The Journal of clinical endocrinology and metabolism.

[150]  W. Hörl,et al.  Reversibility of ‘Secondary Hypercalcitoninemia’ After Kidney Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[151]  E. Kebebew,et al.  Extent of disease and practice patterns for medullary thyroid cancer. , 2005, Journal of the American College of Surgeons.

[152]  H. Holzhausen,et al.  Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. , 2005, The Journal of clinical endocrinology and metabolism.

[153]  J. Breza,et al.  Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome , 2005, Journal of Molecular Medicine.

[154]  M. Rosenthal,et al.  Inherited medullary thyroid cancer and the duty to warn: revisiting Pate v. Threlkel in light of HIPAA. , 2005, Thyroid : official journal of the American Thyroid Association.

[155]  T. Carling,et al.  Parathyroid surgery in familial hyperparathyroid disorders * , 2005, Journal of internal medicine.

[156]  H. Dralle,et al.  Advances in the management of hereditary medullary thyroid cancer , 2005, Journal of internal medicine.

[157]  O. Rorstad,et al.  The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. , 2004, Surgery.

[158]  V. K. Bajpai,et al.  Unraveling the amyloid associated with human medullary thyroid carcinoma. , 2004, Endocrinology.

[159]  A. Pinchera,et al.  Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. , 2004, Thyroid : official journal of the American Thyroid Association.

[160]  C. Sekulla,et al.  Multiple Endocrine Neoplasia 2B Syndrome due to Codon 918 Mutation: Clinical Manifestation and Course in Early and Late Onset Disease , 2004, World Journal of Surgery.

[161]  E. Mallet,et al.  Reference intervals for serum calcitonin in men, women, and children. , 2004, Clinical chemistry.

[162]  O. Dirsch,et al.  Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. , 2004, Thyroid : official journal of the American Thyroid Association.

[163]  H. Okinaga,et al.  RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[164]  Douglas B. Evans,et al.  A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[165]  S. Ismailov,et al.  Postoperative calcitonin study in medullary thyroid carcinoma. , 2004, Endocrine-related cancer.

[166]  G. Irvin,et al.  Progress in the Operative Management of Sporadic Primary Hyperparathyroidism Over 34 Years , 2004, Annals of surgery.

[167]  J. White,et al.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. , 2004, The Journal of clinical endocrinology and metabolism.

[168]  V. Colantuoni,et al.  Genetic prenatal RET testing and pregnancy management of multiple endocrine neoplasia Type II A (MEN2A): A case report , 2004, Journal of endocrinological investigation.

[169]  D. Jaeck,et al.  When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? , 2003, Surgery.

[170]  Bruno D Fornage,et al.  Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. , 2003, Surgery.

[171]  J. Cerutti,et al.  A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[172]  D. Frassica.  General principles of external beam radiation therapy for skeletal metastases. , 2003, Clinical orthopaedics and related research.

[173]  J. Buckner,et al.  Management of brain metastases from thyroid carcinoma , 2003, Cancer.

[174]  E. Baudin,et al.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging , 2003, British Journal of Cancer.

[175]  E. Baudin,et al.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[176]  C. Broelsch,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene , 2003, Langenbeck's Archives of Surgery.

[177]  M. Merino,et al.  Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. , 2003, The Journal of clinical endocrinology and metabolism.

[178]  P. Komminoth,et al.  Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. , 2003, Pediatrics.

[179]  J. Krieger,et al.  A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma. , 2002, The Journal of clinical endocrinology and metabolism.

[180]  P. Parrilla,et al.  Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. , 2002, Journal of the American College of Surgeons.

[181]  P. Igaz,et al.  Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene. , 2002, The Journal of clinical endocrinology and metabolism.

[182]  A. Miyauchi,et al.  Prospective Trial of Unilateral Surgery for Nonhereditary Medullary Thyroid Carcinoma in Patients without Germline RET Mutations , 2002, World Journal of Surgery.

[183]  T. Lairmore,et al.  Gastrointestinal Manifestations of Multiple Endocrine Neoplasia Type 2 , 2002, Annals of surgery.

[184]  M. Béhé,et al.  Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. , 2002, Seminars in nuclear medicine.

[185]  B. Ponder,et al.  Guidelines for diagnosis and therapy of MEN type 1 and type 2. , 2001, The Journal of clinical endocrinology and metabolism.

[186]  T. Schilling,et al.  Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. , 2001, Surgery.

[187]  A Chakravarti,et al.  Hirschsprung disease, associated syndromes and genetics: a review , 2001, Journal of Medical Genetics.

[188]  O. Haas,et al.  Sporadic Versus Familial Medullary Thyroid Microcarcinoma: A Histopathologic Study of 50 Consecutive Patients , 2001, The American journal of surgical pathology.

[189]  S. Bardet,et al.  Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma , 2001, Clinical endocrinology.

[190]  L. Fleisher,et al.  Health Insurance Portability and Accountability Act is here: What price privacy? , 2001, Genetics in Medicine.

[191]  L. Gostin,et al.  National health information privacy: regulations under the Health Insurance Portability and Accountability Act. , 2001, JAMA.

[192]  A. Abbruzzese,et al.  Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer , 2001, British Journal of Cancer.

[193]  H. Siggelkow,et al.  Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. , 2001, European journal of endocrinology.

[194]  B. Boehm,et al.  Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. , 2001, The Journal of clinical endocrinology and metabolism.

[195]  M. Schwab,et al.  Prognostic value of codon 918 (ATG→ACG) RET proto‐oncogene mutations in sporadic medullary thyroid carcinoma , 2001, International journal of cancer.

[196]  R. A. Decker,et al.  Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? , 2000, Surgery.

[197]  M. Papotti,et al.  Thyroid carcinomas with mixed follicular and C-cell differentiation patterns. , 2000, Seminars in diagnostic pathology.

[198]  A. Bockisch,et al.  Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. , 2000, The Journal of clinical endocrinology and metabolism.

[199]  R. Hinze,et al.  Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis , 2000, Cancer.

[200]  A. Abbruzzese,et al.  Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. , 2000, The Journal of clinical endocrinology and metabolism.

[201]  A. Talei,et al.  Medullary Thyroid Carcinoma , 2000, Acta Cytologica.

[202]  M. Ichihara,et al.  A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. , 2000, Biochemical and biophysical research communications.

[203]  E. Baudin,et al.  Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). , 1999, European journal of endocrinology.

[204]  C. Eng,et al.  Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment , 1999, Gut.

[205]  J. Moley,et al.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. , 1999, Annals of surgery.

[206]  A. Miyauchi,et al.  Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation , 1999, Japanese journal of cancer research : Gann.

[207]  R. Hofstra,et al.  Oncological implications of RET gene mutations in Hirschsprung’s disease , 1998, Gut.

[208]  J. White,et al.  Serum calcitonin precursors in sepsis and systemic inflammation. , 1998, The Journal of clinical endocrinology and metabolism.

[209]  L. Mariani,et al.  5‐fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors , 1998, Cancer.

[210]  A. de Leiva,et al.  Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[211]  L. Gaboury,et al.  Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. , 1998, Journal of pediatric surgery.

[212]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[213]  R. A. Decker,et al.  Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. , 1998, Journal of pediatric surgery.

[214]  C. Eng,et al.  Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. , 1998, The Journal of clinical endocrinology and metabolism.

[215]  A. Schauer,et al.  Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? , 1997 .

[216]  L. Mulligan,et al.  Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. , 1997, The Journal of clinical endocrinology and metabolism.

[217]  B. Ponder,et al.  Germline mutation of RET codon 883 in two cases of de novo MEN 2B , 1997, Oncogene.

[218]  C. Tzeng,et al.  Prenatal molecular diagnosis of RET proto-oncogene mutation in multiple endocrine neoplasia type 2A. , 1997, Journal of the Formosan Medical Association = Taiwan yi zhi.

[219]  C. Bieglmayer,et al.  Routine measurement of plasma calcitonin in nodular thyroid diseases. , 1997, The Journal of clinical endocrinology and metabolism.

[220]  L. Mulligan,et al.  Mutation of RET codon 768 is associated with the FMTC phenotype , 1997, Clinical genetics.

[221]  K. Herfarth,et al.  Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. , 1996, Surgery.

[222]  H. K. V. van Amstel,et al.  Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. , 1996, The American journal of medicine.

[223]  K. Fife,et al.  Medullary thyroid cancer: the role of radiotherapy in local control. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[224]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[225]  J. Lee,et al.  Serum calcitonin in small cell carcinoma of the prostate. , 1996, Annals of clinical and laboratory science.

[226]  G. Vitale,et al.  Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α‐2b and octreotide , 1996, Cancer.

[227]  R. Tsang,et al.  Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. , 1996, Thyroid : official journal of the American Thyroid Association.

[228]  N J Soper,et al.  Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms. , 1996, Journal of the American College of Surgeons.

[229]  E. Baudin,et al.  Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[230]  F. Chervenak,et al.  The fetus as a patient: an essential ethical concept for maternal-fetal medicine. , 1996, The Journal of maternal-fetal medicine.

[231]  J. Olson,et al.  Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. , 1996 .

[232]  Lalitha Krishnan,et al.  Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma , 1996, Clinical endocrinology.

[233]  S. Asa,et al.  Concurrent medullary and papillary carcinomas of thyroid with lymph node metastases. A collision phenomenon. , 1996, The American journal of surgical pathology.

[234]  D. Marsh,et al.  The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families , 1996, Clinical endocrinology.

[235]  J. Moley,et al.  Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. , 1995, Surgery.

[236]  H. Dralle,et al.  Pheochromocytoma in multiple endocrine neoplasia type 2: European study , 1995, Journal of internal medicine.

[237]  A. Munnich,et al.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. , 1995, Human molecular genetics.

[238]  C Eng,et al.  Low frequency of germline mutations in the RET proto‐oncogene in patients with apparently sporadic medullary thyroid carcinoma , 1995, Clinical endocrinology.

[239]  B. Ponder,et al.  Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. , 1995, The Journal of clinical endocrinology and metabolism.

[240]  R. A. Decker,et al.  Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. , 1995, Surgery.

[241]  Informed consent, parental permission, and assent in pediatric practice. Committee on Bioethics, American Academy of Pediatrics. , 1995, Pediatrics.

[242]  H. Buhr,et al.  Somatostatin receptor imaging in persistent medullary thyroid carcinoma , 1995, Clinical endocrinology.

[243]  P. Goodfellow,et al.  Parent-of-origin effects in multiple endocrine neoplasia type 2B. , 1994, American journal of human genetics.

[244]  L. Mulligan,et al.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. , 1994, Human molecular genetics.

[245]  H. Gharib,et al.  Increased plasma calcitonin levels in systemic mast cell disease. , 1994, Mayo Clinic proceedings.

[246]  T. van Vroonhoven,et al.  Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. , 1994, The New England journal of medicine.

[247]  B. Pasini,et al.  A Mutation in the RET Protooncogene Associated with Multiple Endocrine Neoplasia Type 2B and Sporadic Medullary Thyroid Carcinoma , 1994 .

[248]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[249]  C. Healey,et al.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. , 1994, Human molecular genetics.

[250]  F. Costantini,et al.  Expression of the c-ret proto-oncogene during mouse embryogenesis. , 1993, Development.

[251]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[252]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[253]  T. Lairmore,et al.  Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes , 1993, Annals of surgery.

[254]  E. Krenning,et al.  In vivo somatostatin receptor imaging in medullary thyroid carcinoma. , 1993, The Journal of clinical endocrinology and metabolism.

[255]  J. Dušková,et al.  [Cytologic diagnosis of medullary carcinoma of the thyroid gland]. , 1993, Ceskoslovenska patologie.

[256]  T. Tomita,et al.  C‐cell hyperplasia in secondary hyperparathyroidism , 1992, Histopathology.

[257]  M. Brennan,et al.  Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. , 1991, The American journal of surgical pathology.

[258]  A. Harris,et al.  LONG‐TERM TREATMENT OF METASTATIC MEDULLARY THYROID CARCINOMA WITH THE SOMATOSTATIN ANALOGUE OCTREOTIDE , 1990, Clinical endocrinology.

[259]  B. Alford,et al.  Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. , 1989, Annals of internal medicine.

[260]  S. Petursson,et al.  Metastatic medullary thyroid carcinoma: Complete response to combination chemotherapy with dacarbazine and 5‐fluorouracil , 1988, Cancer.

[261]  S. Jansson,et al.  Recent results of reoperative surgery in medullary carcinoma of the thyroid. , 1988, Wiener klinische Wochenschrift.

[262]  B. Flourié,et al.  Pathophysiological study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. , 1988, Gut.

[263]  S. Baylin,et al.  Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity , 1986, The British journal of surgery.

[264]  W. Sawyer,et al.  Objective comparison of physical dysfunction after neck dissection. , 1985, American journal of surgery.

[265]  C. Fenoglio-Preiser,et al.  Endocrine changes associated with the human aging process: III. Effect of age on the number of calcitonin immunoreactive cells in the thyroid gland. , 1985, Human pathology.

[266]  J. Ritz,et al.  Activation of a novel human transforming gene, ret, by DNA rearrangement , 1985, Cell.

[267]  M. Saad,et al.  Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. , 1984, The Journal of clinical endocrinology and metabolism.

[268]  A. Miyauchi,et al.  Relation of Doubling Time of Plasma Calcitonin Levels to Prognosis and Recurrence of Medullary Thyroid Carcinoma , 1984, Annals of surgery.

[269]  S. Leeman,et al.  Characterization of neurotensin production by a line of rat medullary thyroid carcinoma cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[270]  L. Deftos,et al.  Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. , 1980, The Journal of clinical endocrinology and metabolism.

[271]  D. Allison,et al.  Rôle of calcitonin in diarrhoea associated with medullary carcinoma of the thyroid. , 1979, Gut.

[272]  W. M. Linehan,et al.  The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma , 1978, Cancer.

[273]  S. Wells,et al.  Provocative Agents and the Diagnosis of Medullary Carcinoma of the Thyroid Gland , 1978, Annals of surgery.

[274]  Y. Shimosato,et al.  Production of calcitonin, adrenocorticotropic hormone, and beta-melanocyte-stimulating hormone in tumors derived from amine precursor uptake and decarboxylation cells. , 1977, Cancer research.

[275]  J. Mattson,et al.  Microfollicular thyroid carcinoma with amyloid rich stroma, resembling the medullary carcinoma of the thyroid (MCT) , 1977, Cancer.

[276]  N. Ishikawa,et al.  Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. , 1976, British Journal of Cancer.

[277]  V. Livolsi,et al.  Demonstration by immunoperoxidase staining of hyperplasia of parafollicular cells in the thyroid gland in hyperparathyroidism. , 1973, The Journal of clinical endocrinology and metabolism.

[278]  A. Sjoerdsma,et al.  Elevated histaminase activity in medullary carcinoma of the thyroid gland. , 1970, The New England journal of medicine.

[279]  A. Tashjian,et al.  Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. , 1968, The New England journal of medicine.

[280]  R A Vickers,et al.  Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid—a syndrome , 1968, Cancer.

[281]  E. D. Williams,et al.  Histogenesis of medullary carcinoma of the thyroid , 1966, Journal of clinical pathology.

[282]  P. L. Munson,et al.  THYROID HYPOCALCEMIC PRINCIPLE AND RECURRENT LARYNGEAL NERVE INJURY AS FACTORS AFFECTING THE RESPONSE TO PARATHYROIDECTOMY IN RATS. , 1963, Endocrinology.

[283]  P. Wermer.  Genetic aspects of adenomatosis of endocrine glands. , 1954, The American journal of medicine.

[284]  J. Jaquet.  Ein Fall von metastasierenden Amyloidtumoren (Lymphosarkom) , 1906, Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin.

[285]  Sajal Gupta,et al.  Cryopreservation of parathyroid tissue: an illustrated technique using the cleveland clinic protocol. , 2013, Journal of the American College of Surgeons.

[286]  W. Mendenhall,et al.  A Literature Review of Late Complications of Radiation Therapy for Head and Neck Cancers: Incidence and Dose Response , 2012 .

[287]  H. Dralle,et al.  Simultaneous Medullary and Papillary Thyroid Cancer: A Novel Entity? , 2011, Annals of Surgical Oncology.

[288]  H. Dralle,et al.  Funktionserhaltende Adrenalektomie bei Nebennierentumoren , 2011, Der Chirurg.

[289]  I. B. Borel Rinkes,et al.  Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[290]  M. Swiontkowski.  Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study , 2010 .

[291]  Sebastiano Filetti,et al.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[292]  Jeffrey E. Lee,et al.  Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think? , 2007, Annals of Surgical Oncology.

[293]  H. Dralle,et al.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma , 2006, Surgery Today.

[294]  H. Holzhausen,et al.  Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? , 2006, Surgery.

[295]  J. Bilezikian,et al.  Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. , 2005, The Journal of clinical endocrinology and metabolism.

[296]  D. O'Kane,et al.  Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. , 2005, Clinical chemistry.

[297]  T. Vrtiska,et al.  Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. , 2005, Mayo Clinic proceedings.

[298]  A. Pinchera,et al.  Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. , 2004, The Journal of clinical endocrinology and metabolism.

[299]  P. Ágoston,et al.  18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[300]  R. Hinze,et al.  Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer , 2001, World Journal of Surgery.

[301]  E. Nitzsche,et al.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels , 2001, European Journal of Nuclear Medicine.

[302]  M. Rothmund,et al.  A RET double mutation in the germline of a kindred with FMTC. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[303]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[304]  H. Sekihara,et al.  Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. , 1999, Internal medicine.

[305]  Bartha Maria Knop.  ASHG statement. Professional disclosure of familial genetic information. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. , 1998, American journal of human genetics.

[306]  D. Chappard,et al.  Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. , 1997, The Journal of clinical endocrinology and metabolism.

[307]  C. Eng,et al.  Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma [4] , 1997 .

[308]  C. Proye,et al.  Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs á Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. , 1996, World Journal of Surgery.

[309]  V. Rohmer,et al.  Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[310]  S. Jansson,et al.  Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. , 1986, Surgery.

[311]  V. Livolsi,et al.  Medullary carcinoma. , 1985, Seminars in diagnostic pathology.

[312]  S. Wells,et al.  Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease , 1984, Cancer.

[313]  B. Hamberger,et al.  Impact of screening on prognosis in the multiple endocrine neoplasia type 2 syndromes: natural history and treatment results in 105 patients. , 1984, Henry Ford Hospital medical journal.

[314]  M. Verdy,et al.  Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. , 1982, Journal of pediatric gastroenterology and nutrition.

[315]  S. Salmon,et al.  Radioiodine in the treatment of medullary carcinoma of the thyroid. , 1979, The Journal of clinical endocrinology and metabolism.

[316]  D. Rimoin,et al.  Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. A possible regulatory defect in the differentiation of chromaffin tissue. , 1968, The New England journal of medicine.

[317]  E. D. Williams,et al.  Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. , 1966, The Journal of pathology and bacteriology.

[318]  J. Hazard,et al.  Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. , 1959, The Journal of clinical endocrinology and metabolism.